Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

690 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study).
Mishima H, Oba K, Sakamoto J, Muro K, Yoshino T, Hyodo I, Maehara Y. Mishima H, et al. Jpn J Clin Oncol. 2012 Feb;42(2):134-8. doi: 10.1093/jjco/hyr180. Epub 2011 Dec 12. Jpn J Clin Oncol. 2012. PMID: 22167662 Free PMC article. Clinical Trial.
UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
Hazama S, Mishima H, Tsunedomi R, Okuyama Y, Kato T, Takahashi K, Nozawa H, Ando H, Kobayashi M, Takemoto H, Nagata N, Kanekiyo S, Inoue Y, Hamamoto Y, Fujita Y, Hinoda Y, Okayama N, Oba K, Sakamoto J, Oka M. Hazama S, et al. Among authors: mishima h. Cancer Sci. 2013 Dec;104(12):1662-9. doi: 10.1111/cas.12283. Epub 2013 Oct 27. Cancer Sci. 2013. PMID: 24033692 Free PMC article. Clinical Trial.
The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues.
Okayama N, Nishioka M, Hazama S, Sakai K, Suehiro Y, Maekawa M, Sakamoto J, Iwamoto S, Kato T, Mishima H, Oka M, Hinoda Y. Okayama N, et al. Among authors: mishima h. Jpn J Clin Oncol. 2011 Feb;41(2):165-71. doi: 10.1093/jjco/hyq173. Epub 2010 Oct 5. Jpn J Clin Oncol. 2011. PMID: 20926413
Is there diversity among UGT1A1 polymorphism in Japan?
Kobayashi M, Hazama S, Takahashi K, Oba K, Okayama N, Nishioka M, Hinoda Y, Oka M, Okamoto K, Maeda H, Nakamura D, Sakamoto J, Mishima H. Kobayashi M, et al. Among authors: mishima h. World J Gastrointest Oncol. 2012 Jul 15;4(7):170-5. doi: 10.4251/wjgo.v4.i7.170. World J Gastrointest Oncol. 2012. PMID: 22848786 Free PMC article.
690 results